Easywell Biomedicals (1799) Fundamentals 2026 — Revenue Analysis | SniperIQ
Easywell Biomedicals (1799) is a TW-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of NT$4.1B, trading at NT
Easywell Biomedicals (1799) has a market capitalization of approximately NT$4.1B, trading at NT
Easywell Biomedicals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Easywell Biomedicals runs a net profit margin of -7.7%, a gross margin of 46.9%, and an operating margin of -6.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Easywell Biomedicals reported revenue of NT$597M for fiscal year 2025, with net income of -NT$73M and earnings per share (EPS) of -0.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Easywell Biomedicals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Easywell Biomedicals carries a debt-to-equity ratio of 0.60x and a current ratio of 2.45x, with a market beta of -0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Easywell Biomedicals (1799) the key facts are: market cap NT$4.1B, revenue NT$597M, 52-week range 27.65-55.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Easywell Biomedicals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.